Musculoskeletal tumors: Use of proton MR spectroscopic imaging for characterization

Journal of Magnetic Resonance Imaging

Volumn 23, Issue 1, 2006, Pages 23-28

  Fayad, Laura M ^a   Bluemke, David A ^a   McCarthy, Edward F ^a   Weber, Kristin L ^b   Barker, Peter B ^a   Jacobs, Michael A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone neoplasms; Bone neoplasms, diagnosis; Bone neoplasms, MR; Magnetic resonance (MR); MR spectroscopy; Specimens; Spectroscopy

Indexed keywords

CHOLINE; TUMOR MARKER;

APPARATUS; ARTICLE; BENIGN TUMOR; BONE MARROW; CHONDROSARCOMA; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FIBROSARCOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LEIOMYOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; METABOLITE; NON INVASIVE MEASUREMENT; OSTEOSARCOMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SARCOMA; SIGNAL DETECTION; SIGNAL NOISE RATIO;

BONE NEOPLASMS; CHOLINE; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS;

EID: 30744443539     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.20448     Document Type: Article

References (23)

1. Kransdorf MJ, Jelinek JS, Moser Jr RP, et al. Soft-tissue masses: diagnosis using MR imaging. AJR Am J Roentgenol 1989;153:541-547.
2. Lundorf E, Keller JO, Nielsen OS, Jensen OM, Christensen T. Can magnetic resonance imaging differentiate between benign and malignant conditions in patients with skeletal or soft tissue tumors?. Ugeskr Laeger 1996;158:1518-1520. [Danish]
3. Ma LD, Frassica FJ, Scott Jr WW, Fishman EK, Zerbouni EA. Differentiation of benign and malignant musculoskeletal tumors: potential pitfalls with MR imaging. Radiographics 1995;15:349-366.
4. Shapeero LG, Vanel D. Imaging evaluation of the response of high-grade osteosarcoma and Ewing sarcoma to chemotherapy with emphasis on dynamic contrast-enhanced magnetic resonance imaging. Semin Musculoskelet Radiol 2000;4:137-146.
5. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-84.
6. Castillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17:1-15.
7. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4:47-52.
8. Haase A, Frahm J, Hanicke W, Matthaei D. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 1985;30:341-344.
9. Oya N, Aoki J, Shinozaki T, Watanabe H, Takagishi K, Endo K. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med 2000;18:193-198.
10. Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology 2004;232:599-605.
11. Schellinger D, Lin CS, Fertikh D, et al. Normal lumbar vertebrae: anatomic, age, and sex variance in subjects at proton MR spectroscopy-initial experience. Radiology 2000;215:910-916.
12. Swindle P, McCredie S, Russell P, et al. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 2003;228:144-151.
13. Lean CL, Newland RC, Ende DA, Bokey EL, Smith IC, Mountford CE. Assessment of human colorectal biopsies by 1H MRS: correlation with histopathology. Magn Reson Med 1993;30:525-533.
14. Lean CL, Delbridge L, Russell P, et al. Diagnosis of follicular thyroid lesions by proton magnetic resonance on fine needle biopsy. J Clin Endocrinol Metab 1995;80:1306-1311.
15. Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997;204:661-666.
16. Lean CL SR, Smith ICP, Russell P, Mountford CE. Accurate diagnosis and prognosis of human cancers by proton MRS and a three stage classification strategy. In: G Webb, editor. Annual reports on NMR spectroscopy. London: Academic Press; 2002. p 71-111.
17. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 2004;19:68-75.
18. Jacobs MA, Horska A, van Zijl PC, Barker PB. Quantitative proton MR spectroscopic imaging of normal human cerebellum and brain stem. Magn Reson Med 2001;46:699-705.
19. Hoekstra HJ, Boeve WJ, Kamman RL, Mooyaart EL. Clinical applicability of human in vivo localized phosphorus-31 magnetic resonance spectroscopy of bone and soft tissue tumors. Ann Surg Oncol 1994;1:504-511.
20. Zlatkin MB, Lenkinski RE, Shinkwin M, et al. Combined MR imaging and spectroscopy of bone and soft tissue tumors. J Comput Assist Tomogr 1990;14:1-10.
21. Redmond OM, Stack JP, Dervan PA, Hurson BJ, Carney DN, Ennis JT. Osteosarcoma: use of MR imaging and MR spectroscopy in clinical decision making. Radiology 1989;172:811-815.
22. Aokl J, Watanabe H, Shinozaki T, et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 2003;32:133-138.
23. Michaelis T, Helms G, Frahm J. Metabolic alterations in brain autopsies: proton NMR identification of free glycerol. NMR Biomed 1996;9:121-124.